These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30796122)

  • 1. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
    Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
    Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of phosphate binders in moderate CKD.
    Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
    J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
    Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
    JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
    Vermeulen EA; Eelderink C; Hoekstra T; van Ballegooijen AJ; Raijmakers P; Beulens JW; de Borst MH; Vervloet MG
    Trials; 2022 Sep; 23(1):769. PubMed ID: 36096824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
    Ureña-Torres P; Prié D; Keddad K; Preston P; Wilde P; Wan H; Copley JB
    BMC Nephrol; 2014 May; 15():71. PubMed ID: 24885942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
    Seifert ME; de las Fuentes L; Rothstein M; Dietzen DJ; Bierhals AJ; Cheng SC; Ross W; Windus D; Dávila-Román VG; Hruska KA
    Am J Nephrol; 2013; 38(2):158-67. PubMed ID: 23941761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.
    Bressendorff I; Hansen D; Schou M; Kragelund C; Brandi L
    BMJ Open; 2017 Jun; 7(6):e016795. PubMed ID: 28645983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I; Haffner D; Leifheit-Nestler M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
    Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.